Canaccord lowered the firm’s price target on Zimmer Biomet (ZBH) to $93 from $101 and keeps a Hold rating on the shares. The firm updated its model following Q3 results and subsequent 10Q release. They noted the company tightened its guidance and reiterated reported growth of 6.7-7.7% with the FNA acquisition expected to contribute roughly 270bps to growth.
Discover how TipRanks’ ETF AI Analyst can help you make smarter investment decisions
Explore ETFs TipRanks’ users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ZBH:
Disclaimer & DisclosureReport an Issue
Zimmer Biomet price target lowered to $88 from $96 at UBS
Zimmer Biomet price target lowered to $117 from $125 at Baird
Zimmer Biomet Reports Strong Q3 2025 Earnings
Zimmer Biomet price target lowered to $97 from $106 at Goldman Sachs
Zimmer Biomet’s Earnings Call: Growth Amid Challenges
